Advertisement

Apoptosis

, Volume 10, Issue 5, pp 927–939 | Cite as

The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis

  • A. M. Elsharkawy
  • F. Oakley
  • D. A. MannEmail author
Article

Abstract

Liver fibrosis and its end-stage disease cirrhosis are major world health problems arising from chronic injury of the liver by a variety of etiological factors including viruses, alcohol and drug abuse, the metabolic syndrome, autoimmune disease and hereditary disorders of metabolism. Fibrosis is a progressive pathological process in which wound-healing myofibroblasts of the liver respond to injury by promoting replacement of the normal hepatic tissue with a scar-like matrix composed of cross-linked collagen. Until recently it was believed that this process was irreversible. However emerging experimental and clinical evidence is starting to show that even cirrhosis is potentially reversible. Key to this is the discovery that reversion of fibrosis is accompanied by clearance of hepatic stellate cells (HSC) by apoptosis. Furthermore, proof-of-concept studies in rodents have demonstrated that experimental augmentation of HSC apoptosis will promote the resolution of fibrosis. Consequently there is now considerable interest in determining the molecular events that regulate HSC apoptosis and the discovery of drugs that will stimulate HSC apoptosis in a selective manner. This review will consider the regulatory role played by growth factors (e.g. NGF, IGF-1, TGFβ), death receptor ligands (TRAIL, FAS), components and regulators of extracellular matrix (integrins, collagen, matrix metalloproteinases and their tissue inhibitors) and signal transduction proteins and transcription factors (Rho/Rho kinase, Jun N-terminal Kinase (JNK), IkappaKinase (IKK), NF-κ B). The potential for known pharmacological agents such as gliotoxin, sulfasalazine, benzodiazepine ligands, curcumin and tanshinone I to induce HSC apoptosis and therefore to be used therapeutically will be explored.

Keywords

apoptosis hepatic stellate cells liver fibrosis NF-kB 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jaeschke H. Cellular adhesion molecules: Regulation and functional significance in the pathogenesis of liver diseases. Am J Physiol Gastroinest Liver Physiol 1997; 273; G602–G611.Google Scholar
  2. 2.
    Pinzani M, Marra F. Cytokine receptors and signalling in hepatic stellate cells. Semin Liver Dis 2001; 21: 397–426.CrossRefPubMedGoogle Scholar
  3. 3.
    Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247–2250.CrossRefPubMedGoogle Scholar
  4. 4.
    Fallowfield JA, Iredale JP. Reversal of liver fibrosis and cirrhosis–an emerging reality. Scott Med J 2004; 49: 3–6.PubMedGoogle Scholar
  5. 5.
    Pinzani M, Rombouts K. Liver fibrosis: From the bench to clinical targets. Dig Liver Dis 2004; 36: 231–242.CrossRefPubMedGoogle Scholar
  6. 6.
    Knittel T, Kobold D, Saile B, et al. Rat liver myofibroblasts and hepatic stellate cells: Different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999; 117: 1205–1221.PubMedGoogle Scholar
  7. 7.
    Forbes SJ, Russo FP, Rey V, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004; 126: 955–963.CrossRefPubMedGoogle Scholar
  8. 8.
    Iredale JP. Cirrhosis: New research provides a basis for rational and targeted treatment. BMJ 2003; 327: 143–147.CrossRefPubMedGoogle Scholar
  9. 9.
    Friedman SL. The cellular basis of hepatic fibrosis: Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1823–1835.Google Scholar
  10. 10.
    Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: The principle collagen producing cells of normal rat liver. Proc Natl Acad Sci USA 1985; 82: 8681–8685.PubMedGoogle Scholar
  11. 11.
    Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001; 21: 417–426.CrossRefPubMedGoogle Scholar
  12. 12.
    Iredale JP, Benyon RC, Arthur MJP, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA in experimental liver injury and fibrosis. Hepatology 1996; 24: 176–184.PubMedGoogle Scholar
  13. 13.
    Arthur MJP, Iredale JP, Mann DA. Tissue inhibitors of metalloproteinases: Role in liver fibrosis and alcoholic liver disease. Alcohol Clin Exp Res 1999; 23: 940–943.PubMedGoogle Scholar
  14. 14.
    Bonis PAL, Freidman SL, Kaplan MM. Is liver fibrosis reversible. N Engl J Med 2001; 344: 452–454.CrossRefPubMedGoogle Scholar
  15. 15.
    Arthur MJP. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122: 1525–1528.CrossRefPubMedGoogle Scholar
  16. 16.
    Poynard T, McHutchinson J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303–1313.CrossRefPubMedGoogle Scholar
  17. 17.
    Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997; 127: 981–985.PubMedGoogle Scholar
  18. 18.
    Wanless IR. Use of corticosteroid therapy in autoimmune hepatitis resulting in resolution of cirrhosis. J Clin Gastroenterol 2001; 32: 371–372.CrossRefPubMedGoogle Scholar
  19. 19.
    Kaplan MM, DeLillis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997; 126: 682–688.PubMedGoogle Scholar
  20. 20.
    Kweon YO, Goodman ZD, Dienstag JL, et al. Decreasing fibrogenesis: An immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001; 35: 749–755.CrossRefPubMedGoogle Scholar
  21. 21.
    Hammel P, Coulevard A, O’Toole D, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001; 344: 418–423.CrossRefPubMedGoogle Scholar
  22. 22.
    Fogo AB. Mesangial matrix modulation and glomerulosclerosis. Exp Nephrol 1999; 7: 147–159.CrossRefPubMedGoogle Scholar
  23. 23.
    Yang F, Yang XP, Liu YH, et al. Ac-SKDP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004; 43: 229–236.CrossRefPubMedGoogle Scholar
  24. 24.
    Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis—hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538–549.PubMedGoogle Scholar
  25. 25.
    Issa R, Williams E, Trim N, et al. Apoptosis of hepatic stellate cells: Involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48: 548– 557.CrossRefPubMedGoogle Scholar
  26. 26.
    Salvesen GS, Abrams JM. Caspase activation—stepping on the gas or releasing the brakes? Oncogene 2004; 23: 2774–2784.CrossRefPubMedGoogle Scholar
  27. 27.
    Norbury CJ and Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004; 23: 2797–2808.CrossRefPubMedGoogle Scholar
  28. 28.
    Canbay A, Friedman S, Gores GJ. Apoptosis: The nexus of liver injury and fibrosis. Hepatology 2004; 39: 273–278.CrossRefPubMedGoogle Scholar
  29. 29.
    Lee JI, Lee KS, Paik YH, et al. Apoptosis of hepatic stellate cells in carbon tetrachloride induced acute liver injury of the rat: Analysis of isolated hepatic stellate cells. J Hepatol 2003; 39: 960–966.CrossRefPubMedGoogle Scholar
  30. 30.
    Wright MC, Issa R, Smart DE, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances resolution of fibrosis in rats. Gastroenterology 2001; 121: 685–698.CrossRefPubMedGoogle Scholar
  31. 31.
    Jaatela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004; 23: 2746–2756.PubMedGoogle Scholar
  32. 32.
    Trim N, Issa R, Krane S, Benyon RC, Iredale JP. Intact collagen-1 inhibits hepatic stellate cell activation and promotes persistence of activated HSC in vivo. Hepatology 2000; 32: 183A.Google Scholar
  33. 33.
    Issa R, Zhou X, Trim N, et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J 2003; 17: 47–49.PubMedGoogle Scholar
  34. 34.
    Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: Evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126: 1795–1808.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhou X, Murphy FR, Gedhu N, Zhang J, Iredale JP, Benyon RC. Engagement of αvβ3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem 2004; 279: 23996–24006.CrossRefPubMedGoogle Scholar
  36. 36.
    Iwamoto H, Sakai H, Tada S, Nakamuta M, Nawata H. Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion. J Lab Clin Med 1999; 134: 83–89.CrossRefPubMedGoogle Scholar
  37. 37.
    Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects in matrix metalloproteinase inhibition. J Biol Chem 2002; 277: 11069–11076.CrossRefPubMedGoogle Scholar
  38. 38.
    Yoshiji H, Kuriyama S, Yoshii J, et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002; 36: 850–860.PubMedGoogle Scholar
  39. 39.
    Preaux AM, D’ortho MP, Bralet MP, Laperche Y, Mavier P. Apoptosis of human human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2. Hepatology 2002; 36: 615–622.CrossRefPubMedGoogle Scholar
  40. 40.
    Liu XW, Bernardo MM, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 2003; 278: 40364–40372.CrossRefPubMedGoogle Scholar
  41. 41.
    Murphy F, Wuang J, Collins J, et al. N-Cadherin cleavage during activated hepatic stellate cell apoptosis is inhibited by tissue inhibitor of metalloproteinase-1. Comp Hepatol 2004; 3: S8.CrossRefGoogle Scholar
  42. 42.
    Liu XJ, Yang L, Wu H-B, Qiang O, Huang MH, Wang YP. Apoptosis of rat hepatic stellate cells induced by anti-focal adhesion kinase antibody. World J Gastroenterol 2002; 8: 734–738.PubMedGoogle Scholar
  43. 43.
    Fischer R, Cariers A, Reinehr R, Haussinger D. Caspase 9 dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology 2002; 123: 845–861.CrossRefPubMedGoogle Scholar
  44. 44.
    Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188–1198.CrossRefPubMedGoogle Scholar
  45. 45.
    Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56–65.CrossRefPubMedGoogle Scholar
  46. 46.
    Trim N, Morgan S, Evans M, et al. Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am J Pathol 2000; 156: 1235–1243.PubMedGoogle Scholar
  47. 47.
    Oakley F, Trim N, Constandinou CM, et al. Hepatocytes express nerve growth factor during liver injury. Am J Pathol 2003; 163: 1849–1858.PubMedGoogle Scholar
  48. 48.
    Saile B, DeRocco P, Dudas J, et al. IGF-I induces DNA synthesis and apoptosis in rat liver hepatic stellate cells (HSC) but DNA synthesis and proliferation in rat liver myofibroblasts (rMF). Lab Invest 2004; 84: 1037–1049.CrossRefPubMedGoogle Scholar
  49. 49.
    Saile B, Matthes N, Knittel T, Ramadori G. Transforming growth factor beta and tumour necrosis factor alpha inhibit both apoptosis and proliferation of activated hepatic stellate cells. Hepatology 1999; 30: 196–202.CrossRefPubMedGoogle Scholar
  50. 50.
    Saile B, Matthes N, El Armouche H, Neubauer K, Ramadori G. The blc, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta and TNF-alpha on activated hepatic stellate cells. Eur J Cell Biol 2001; 80: 554–561.CrossRefPubMedGoogle Scholar
  51. 51.
    Varela-Ray M, Montiel-Duarte C, Oses-Prieto JA, et al. p38 MAPK mediates the regulation of α 1(I) procollagen mRNA levels by TNF-α and TGF-β in a cell line of rat hepatic stellate cells. FEBS Letters 2002; 528: 133–138.CrossRefPubMedGoogle Scholar
  52. 52.
    Saile B, Knittel T, Matthes N, Schott P, Ramadori G. CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during tissue repair. Am J Pathol 1997; 151: 1265–1272.PubMedGoogle Scholar
  53. 53.
    Gong W, Pecci A, Roth S, Lahme B, Beato M, Gressner AM. Tranformation-dependent susceptibility of rat hepatic stellate cells to apoptosis induced by soluble Fas ligand. Hepatology 1998; 28: 492–502.CrossRefPubMedGoogle Scholar
  54. 54.
    Saile B, Matthes N, Neubauer K, et al. Rat liver myofibroblasts and hepatic stellate cells differ in CD95-mediated apoptosis and response to TNF-α. Am J Physiol Gastrointest Liver Phsiol 2001; 283: G435–G444.Google Scholar
  55. 55.
    Cariers A, Reinehr R, Fischer R, Warskulat U, Haussinger D. c-Jun-N-terminal kinase dependent membrane targeting of CD95 in rat hepatic stellate cells. Cell Physiol Biochem 2002; 12: 179–186.CrossRefPubMedGoogle Scholar
  56. 56.
    Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004; 23: 2950–2966.CrossRefPubMedGoogle Scholar
  57. 57.
    Wang XZ, Zhang SJ, Chen YX, Chen ZX, Huang YH, Zhang LJ. Effects of platelet-derived growth factor and interleukin-10 on Fas/Fas-ligand and Bcl-2/Bax mRNA expression in rat hepatic stellate cells in vitro. World J Gastroenterol 2004; 10: 2706–2710.PubMedGoogle Scholar
  58. 58.
    Thompson K, Maltby J, Fallowfield J, McAulay M, Millwall-Sadler H, Sheron N. Interleukin-10 expression and function in experimental murine inflammation and fibrosis. Hepatology 1998; 28: 1597–1606.CrossRefPubMedGoogle Scholar
  59. 59.
    Galle PR, Hofmann WJ, Walczak H, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223–1230.CrossRefPubMedGoogle Scholar
  60. 60.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806–809.CrossRefPubMedGoogle Scholar
  61. 61.
    Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: A link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323–1330.CrossRefPubMedGoogle Scholar
  62. 62.
    Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL mediated apoptosis. Hepatology 2003; 37: 87–95.CrossRefPubMedGoogle Scholar
  63. 63.
    Saile B, Eisenbach C, El-Armouche H, Neubauer K, Ramadori G. Anti-apoptotic effect of interferon-alpha on hepatic stellate cells (HSC): A novel pathway of IFN-alpha signal transduction via Janus kinase 2 (JAK2) and caspase 8. Eur J Cell Biol 2003; 82: 31–41.CrossRefPubMedGoogle Scholar
  64. 64.
    Saile B, Eisenbach C, Hammoudeh E, Ramadori G. Interferon-γgcts proapoptotic on hepatic stellate cell (HSC) and abrogates the antiapoptotic effect of interferon-α by an HSP70-dependant pathway. Eur J Cell Biol 2004; 83: 469–476.CrossRefPubMedGoogle Scholar
  65. 65.
    Reynaert H, Rombouts K, Vandermonde A, et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004; 53: 1180–1189.CrossRefPubMedGoogle Scholar
  66. 66.
    Pan Q, Li DG, Lu HM, Lu IY, Wang YQ, Xu QF. Antiproliferative and proapoptotic effects of somatostatin on activated hepatic stellate cells. World J Gastroenterol 2004; 10: 1015–1018.PubMedGoogle Scholar
  67. 67.
    Oben JA, Roskams T, Yang S, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 2004; 53: 438–445.CrossRefPubMedGoogle Scholar
  68. 68.
    Fischer R, Schmitt M, Bode JG, Haussinger D. Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology 2001; 120: 1212–1226.CrossRefPubMedGoogle Scholar
  69. 69.
    Saxena NK, Titus MA, Ding X, et al. Leptin is a novel profibrogenic cytokine in hepatic stellate cells: Mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (erk) and Akt phosphorylation. FASEB J 2004; 18: 1612–1614.PubMedGoogle Scholar
  70. 70.
    Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002; 35: 762–771.CrossRefPubMedGoogle Scholar
  71. 71.
    Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 2004; 30: 121–138.PubMedGoogle Scholar
  72. 72.
    Zamara E, Novo E, Marra F, et al. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004; 40: 60–68.CrossRefPubMedGoogle Scholar
  73. 73.
    Davaille J, Li L, Mallat A, Lotersztajn S. Sphingosine 1-phosphate triggers both apoptotic and survival for human hepatic myofibroblasts. J Biol Chem 2002; 277: 37323–37330.Google Scholar
  74. 74.
    Zu J, Fu Y, Chen A. Activation of peroxisome proliferator-activated receptor-γ contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 2003; 285: G20–G30.PubMedGoogle Scholar
  75. 75.
    Galli A, Crabb D, Price D, et al. Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells. Hepatology 2000; 31: 101–108.CrossRefPubMedGoogle Scholar
  76. 76.
    Zheng S, Chen A. Activation of PPAR-γ is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cell in vitro. Biochem J 2004; 384: 149–57.CrossRefPubMedGoogle Scholar
  77. 77.
    Montiel-Duarte C, Ansorena E, Lopez-Zabalza MJ, Cenarruzabeitia E, Iraburu MJ. Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxymethamphetamine (“Ecstasy”) on hepatic stellate cells. Biochem Pharmacol 2004; 67: 1025–1033.CrossRefPubMedGoogle Scholar
  78. 78.
    Thirunavukkarasu C, Watkins S, Harvey R, Gandhi C. Superoxide-induced apoptosis of activated rat hepatic stellate cells. J Hepatol 2004; 41: 567–575.CrossRefPubMedGoogle Scholar
  79. 79.
    Zhu J, Wu J, Frizell E, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117: 1198–1204.PubMedGoogle Scholar
  80. 80.
    Zhao YZ Kim JY, Park EJ, et al. Tetrandrine induces apoptosis in hepatic stellate cells. Phytother Res 2004; 18: 306–309.CrossRefPubMedGoogle Scholar
  81. 81.
    Kim JY, Kim KM, Nan JX, et al. Induction of apoptosis by tanshinone I via cytochrome c release in activated hepatic stellate cells. Pharmacol Toxicol 2003; 92: 195–200.CrossRefPubMedGoogle Scholar
  82. 82.
    Zhang XL, Liu L, Jiang HQ. Salvia miltiorrhiza monomer IH764-3 induces hepatic stellate cell apoptosis via caspase-3 activation. World J Gastroenterol 2002; 8: 515–519.PubMedGoogle Scholar
  83. 83.
    Yao XX, Tang YW, Yao DM, Xiu HM. Effects of Yigan Decoction on proliferation and apoptosis of hepatic stellate cells. World J Gastroenterol 2002; 8: 511–514.PubMedGoogle Scholar
  84. 84.
    Zhao WX, Zhao J, Liang CL, Zhao B, Pang RQ, Pan XH. Effect of caffeic acid phenethyl ester on proliferation and apoptosis of hepatic stellate cells in vitro. World J Gastroenterol 2003; 9: 1278–1281.PubMedGoogle Scholar
  85. 85.
    Dekel R, Zvibel I, Brill S, Brazovsky E, Halpern Z, Oren R. Gliotoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide rat model. Dig Dis Sci 2003; 48: 1642–1647.CrossRefPubMedGoogle Scholar
  86. 86.
    Orr JG, Leel V, Cameron GA, et al. Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells. Hepatology 2004; 40: 232–242.CrossRefPubMedGoogle Scholar
  87. 87.
    Kweon YO, Paik YH, Schnabl B, Qian T, Lemasters JJ, Brenner DA. Gliotoxin-mediated apoptosis of activated human hepatic stellate cells. J Hepatol 2003; 39: 38–46.CrossRefPubMedGoogle Scholar
  88. 88.
    Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004; 308: 1191–1196.CrossRefPubMedGoogle Scholar
  89. 89.
    Canbay A, Guicciardi ME, Higuchi H, et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 2003; 112: 152–159.CrossRefPubMedGoogle Scholar
  90. 90.
    Abriss B, Hollweg G, Gressner AM, Weiskirchen R. Adenoviral mediated transfer of p53 or retinoblastoma protein blocks cell proliferation and induces apoptosis in culture-activated hepatic stellate cells. J Hepatol 2003; 38: 169–178.CrossRefPubMedGoogle Scholar
  91. 91.
    Janeschek N, van de Leur E, Gressner AM, Weiskirchen R. Induction of cell death in activated hepatic stellate cells by targeted gene expression of the thymidine kinase/ganciclovir system. Biochem Biophys Res Commun 2004; 316: 1107–1115.CrossRefPubMedGoogle Scholar
  92. 92.
    Pahl HL. Activators and target genes of Rel/NF-ΚB transcription factors. Oncogene 1999; 18: 6853–6866.CrossRefPubMedGoogle Scholar
  93. 93.
    Baldwin AS. The transcription factor NF-ΚB and human disease. J Clin Invest 2001; 107: 3–6.PubMedGoogle Scholar
  94. 94.
    Ghosh S, May MJ, Kopp EB. NF-ΚB and rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225–260.PubMedGoogle Scholar
  95. 95.
    Elsharkawy AM, Wright MC, Hay RT, et al. Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel rel-like factors and prolonged changes in the expression of IkappaB family proteins. Hepatology 1999; 30: 761–769.CrossRefPubMedGoogle Scholar
  96. 96.
    Hellebrand C, Jobin C, Licato LL, Sartor RB, Brenner DA. Inhibition of NF-kappaB in activated rat hepatic stellate cells by proteosome inhibitors and an IkappaB super-repressor. Hepatology 1998; 27: 1285–1295.CrossRefPubMedGoogle Scholar
  97. 97.
    Baeuerle PA, Baltimore D. NFkappaB: Ten years after. Cell 1996; 87: 13–20.CrossRefPubMedGoogle Scholar
  98. 98.
    Hetts SW. To die or not to die; an overview of apoptosis and its role in disease. JAMA 1998; 279: 300–307.CrossRefPubMedGoogle Scholar
  99. 99.
    Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-ΚB anti-apoptosis: Induction of TRAF-1, TRAF-2, c-IAP1 and c-IAP2 to suppress caspase 8 activation. Science 1998; 281: 1680–1683.Google Scholar
  100. 100.
    Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2003; 3: 221–227.CrossRefGoogle Scholar
  101. 101.
    Lang A, Schoonhoven R Tuvia S, Brenner DA, Rippe RA. Nuclear factor kappaB in proliferation, activation and apoptosis in rat hepatic stellate cells. J Hepatol 2000; 33: 49–58.CrossRefPubMedGoogle Scholar
  102. 102.
    Oakley F, Meso M, Iredale JP, et al. Inhibition of IΚB kinases stimulates hepatic stellate cell apoptosis and accelerates recovery from liver fibrosis. Gastroenterology 2005; 128: 108–120.CrossRefPubMedGoogle Scholar
  103. 103.
    Wahl C, Liptay S, Adler G, Schmit RM. Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998; 101: 1163–1174.PubMedGoogle Scholar
  104. 104.
    Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 2002; 277: 3863–3869.CrossRefPubMedGoogle Scholar
  105. 105.
    Papa S, Zazzeroni F, Bubici C, et al. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol 2004; 6: 146–153.CrossRefPubMedGoogle Scholar
  106. 106.
    Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838–2849.PubMedGoogle Scholar
  107. 107.
    Bahr MJ, Vincent KJ, Arthur MJP, et al. Control of the tissue inhibitor of metalloproteinases-1 promoter in culture-activated rat hepatic stellate cells: Regulation by activator protein-1 DNA binding proteins. Hepatology 1999; 29: 839–848.CrossRefPubMedGoogle Scholar
  108. 108.
    Czaja MJ. JNK/AP-1 regulation of hepatocyte death. Am J Physiol Gastroinest Liver Physiol 2003; 284: G875–G879.Google Scholar
  109. 109.
    Uyama N, Shimahara Y, Okuyama H, et al. Carbenoxlone inhibits DNA synthesis and collagen gene expression in rat hepatic stellate cells in culture. J Hepatol 2003; 39: 749–755.CrossRefPubMedGoogle Scholar
  110. 110.
    Ikeda H, Nagahima K, Yanase M, et al. Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am J Physiol Gastroinest Liver Physiol 2003; 285: G880–G886.Google Scholar
  111. 111.
    Saelens X, Festjens N, Vande Malle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene 2004; 23: 2861–2874.CrossRefPubMedGoogle Scholar
  112. 112.
    Kawada N, Kristensen DB, Asahina K, et al. Characterisation of a stellate cell activation-associated (STAP) with peroxidase activity found in rat hepatic stellate cells. J Biol Chem 2001; 276: 25318–25323.CrossRefPubMedGoogle Scholar
  113. 113.
    Liu XJ, Yang L, Luo FM, Wu HB, Qiang Q. Association of differentially expressed genes with activation of mouse hepatic stellate cells by high density cDNA microarray. World J Gastroenterol 2004; 10: 1600–1607.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Liver Group, Division of Infection, Inflammation and RepairUniversity of Southampton, Southampton General HospitalSouthamptonUK

Personalised recommendations